OKYO Pharma Appoints Blockbuster Orphan Drug Veteran as Chief Medical Officer

summarizeSummary

OKYO Pharma announced the appointment of Dr. Flavio Mantelli, a highly experienced ophthalmology drug developer, as its new Chief Medical Officer, bringing critical expertise for advancing its lead candidate, urcosimod.

check_boxKey Events

• New Chief Medical Officer Appointed

  Dr. Flavio Mantelli, MD, PhD, has been named Chief Medical Officer, effective February 10, 2026.

• Proven Orphan Drug Development Expertise

  Dr. Mantelli previously led the successful clinical development and regulatory approval of Oxervate®, an orphan drug that achieved over $1 billion in annual sales.

• Strategic Alignment with Pipeline

  Dr. Mantelli will lead the clinical and regulatory strategy for urcosimod, OKYO's lead candidate for neuropathic corneal pain, which has FDA Fast Track designation.

• Strengthens Leadership Team

  This appointment further builds out OKYO's executive team, following the recent CEO appointment, bringing world-class ophthalmology leadership.

auto_awesomeAnalysis

The appointment of Dr. Flavio Mantelli as Chief Medical Officer is a significant positive development for OKYO Pharma. Dr. Mantelli's unparalleled experience in ocular surface drug development, including leading the successful clinical development and regulatory approval of Oxervate® (a blockbuster orphan drug with over $1 billion in sales), directly aligns with OKYO's strategic focus on neuropathic corneal pain (NCP) and its lead candidate, urcosimod. This hire, following the recent CEO appointment, substantially strengthens the company's leadership team and enhances its capabilities to navigate clinical trials and regulatory pathways for its pipeline, particularly given urcosimod's FDA Fast Track designation.